Resources Antibody Industry Trends Week 5, Apr 2024: Immunosenescence

Week 5, Apr 2024: Immunosenescence

Biointron 2024-04-30 Read time: 3 mins
DOI: 10.3389/fimmu.2020.579220

As we age, our innate and adaptive immune system undergoes various changes, typically characterized by decreased lymphopoiesis and adaptive immunity, and increased inflammation and myeloid pathologies. Immunosenescence (the gradual deterioration of the immune system associated with ageing), makes individuals more susceptible to infections, less responsive to vaccines, and prone to the development of chronic inflammatory conditions and autoimmune diseases. Additionally, age-related alterations in the composition and function of the microbiota, the community of microorganisms living in and on the body, can further influence immune function and contribute to the overall ageing process.

This month, several papers related to antibodies and aging were published, including a comprehensive review by Quiros-Roldan et al., studying the impact of immune system aging on infectious diseases, including the progressive reduction of the body’s ability to trigger effective antibody responses. Here they describe the increased public interest in immune system aging due to prolonged life expectancy, contrasted to health expectancy. They also provide an analysis of the immune players involved, in addition to immune cells/mediators within endogenous and exogenous factors and co-morbidities.

Another paper this month provides insight into why age is a major risk factor for severe COVID-19. By evaluating the impact of aging and anti-IFN autoantibodies on host immune response in the blood, upper airway, and nasal microbiome, the researchers found that older age correlated with impaired viral clearance, dysregulated immune signaling, and persistent and potentially pathologic activation of pro-inflammatory genes and proteins.

Ending on a bright note, Ross et al.’s study in Nature demonstrates the antibody-mediated depletion of my-haematopoietic stem cells (HSCs) in aged mice restores characteristic features of a more youthful immune system. Their findings show it might be possible to reverse the ageing phenotype by eliminating my-HSCs in aged mice and contributes to the understanding and intervention of diseases exacerbated or caused by dominance of the haematopoietic system by my-HSCs.

Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.